Transcode Therapeutics Inc. (RNAZ)

Q2 2024 EPS Estimates for TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Decreased by Analyst

TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) – Equities research analysts at HC Wainwright reduced their Q2 2024 earnings per share estimates for shares of TransCode Therapeutics in a research report issued on Thursday, May 16th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.58) per share for the quarter, down from their previous estimate of ($0.50). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for TransCode Therapeutics’ current full-year earnings is ($1.98) per share. HC Wainwright also issued estimates for TransCode Therapeutics’ Q3 2024 earnings at ($0.35) EPS, Q4 2024 earnings at ($0.39) EPS, FY2024 earnings at ($1.98) EPS, FY2026 earnings at ($0.47) EPS and FY2028 earnings at ($0.39) EPS. TransCode Therapeutics Stock Performance TransCode Therapeutics stock opened at $1.15 on Monday. TransCode Therapeutics has a fifty-two week low of $0.42 and a fifty-two week high of $309.60. The company has a market capitalization of $7.61 million, a P/E ratio of 0.00 and a beta of -0.36. The stock has a 50-day simple moving average of $0.70 and a 200-day simple moving average of $3.73. Institutional Trading of TransCode Therapeutics A hedge fund recently raised its stake in TransCode Therapeutics stock. Sabby Management LLC raised its stake in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) by 32.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 250,309 shares of the company’s stock after acquiring an additional 61,872 shares during the period. Sabby Management LLC owned approximately 12.33% of TransCode Therapeutics worth $126,000 as of its most recent SEC filing. About TransCode Therapeutics (Get Free Report) TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Read More Five stocks we like better than TransCode Therapeutics Bank Stocks – Best Bank Stocks to Invest In MarketBeat Week in Review – 5/13 – 5/17 How to Use the MarketBeat Dividend Calculator Take-Two Interactive Software Offers 2nd Chance for Investors The Top 3 Healthcare Dividend Stocks to Buy and Hold Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook